Kodiak Sciences (KOD) Income from Continuing Operations (2017 - 2026)
Kodiak Sciences (KOD) reported Income from Continuing Operations of 58136000.0 for Q1 2026, down 1.16% on a YoY basis from 58816569.66 in Q1 2025, and down 2.54% quarter-over-quarter from 56696000.0 in Q4 2025.
Kodiak Sciences (KOD) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Kodiak Sciences has reported Income from Continuing Operations for 10 years, with the latest figure at 58136000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 1.16% year-over-year to 58136000.0; the trailing twelve-month figure through Mar 2026 stood at 230536000.0 (down 21.04% YoY), and the FY2025 full-year result was 229871000.0, down 30.83% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 58136000.0, down from 56696000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 42702000.0 in Q1 2024, with the low at 95696000.0 in Q1 2022.
- Historically, Income from Continuing Operations has averaged 62272647.06 across 5 years, with a median of 58136000.0 in 2026.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations sank 89.82% — and 2024, when it soared 43.82%.
- Kodiak Sciences' Income from Continuing Operations stood at 71053000.0 in 2022, then climbed by 16.29% to 59477000.0 in 2023, then grew by 25.94% to 44049000.0 in 2024, then slipped by 28.71% to 56696000.0 in 2025, then fell by 2.54% to 58136000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 58136000.0 (Q1 2026), 56696000.0 (Q4 2025), and 61435000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -56.48 Mn |
| 10 | Kodiak Sciences | 1.95 Bn | 1.95 Bn | - | -58.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -58.14 Mn |
| Dec 31, 2025 | -56.70 Mn |
| Sep 30, 2025 | -61.44 Mn |
| Jun 30, 2025 | -54.27 Mn |
| Mar 31, 2025 | -57.47 Mn |
| Dec 31, 2024 | -44.05 Mn |
| Sep 30, 2024 | -43.92 Mn |
| Jun 30, 2024 | -45.03 Mn |
| Mar 31, 2024 | -42.70 Mn |
| Dec 31, 2023 | -59.48 Mn |
| Sep 30, 2023 | -49.97 Mn |
| Jun 30, 2023 | -80.15 Mn |
| Mar 31, 2023 | -71.00 Mn |
| Dec 31, 2022 | -71.05 Mn |
| Sep 30, 2022 | -77.00 Mn |
| Jun 30, 2022 | -90.58 Mn |
| Mar 31, 2022 | -95.70 Mn |
| Dec 31, 2021 | -93.05 Mn |
| Sep 30, 2021 | -67.50 Mn |
| Jun 30, 2021 | -55.83 Mn |